Navigation Links
Bionovo to Present Positive Results from Phase 2 Trial of Menerba for Vasomotor Symptoms to the International Community
Date:9/3/2009

EMERYVILLE, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) announced it will be presenting the positive results from the phase 2 clinical trial of their lead drug candidate for postmenopausal symptoms, Menerba, to the international community at the 8th Annual European Society for Gynecology (EGS) in Rome, Italy.

The phase 2 clinical trial was designed to evaluate the safety and efficacy of two doses of Menerba versus placebo. The trial was a randomized, double-blinded, placebo-controlled study that enrolled 217 healthy postmenopausal women reporting moderate to severe hot flashes. Highlights from the trial include:

  • After 12 weeks of treatment, there was a statistically significant decrease in frequency of all hot flashes in the higher dose of Menerba (p=0.04).
  • There was a clear dose response trend in multiple efficacy analyses.
  • Menerba reduced the number of times women were awakened from sleep due to hot flashes (night sweats). The median percent reduction in night sweats in the higher dose of Menerba was 67%, statistically superior to placebo (p=0.05).
  • Compliance and study retention was excellent: 98% of participants completed the trial, with 91% of participants taking at least 75% of the assigned study medication.
  • The only statistically significant adverse event was "transient loose stools" (12% on Menerba vs. 3% on placebo).
  • During the trial, there was no difference in the number of uterine bleeding episodes between the treatment groups and placebo and no cases of endometrial hyperplasia or uterine cancer, further demonstrating Menerba's excellent safety profile.
  • After 12 weeks of treatment, participants taking Menerba experienced lower body mass index and weight compared to those on placebo.

"The novel mechanism of action, the positive efficacy results and the excellent safety profile, make Menerba an extremely promising drug candidate for postmenopausal women. While 40 million women in the United States suffer from hot flashes and night sweats leading to the second largest indication in Women's Health domestically, the opportunity is significantly increased when we factor in international opportunities. We look forward to introducing Menerba to a wider scientific, clinical and pharmaceutical community, where there is demonstrated interest in finding an alternative to hormone therapy on an international basis," said Dr. Mary Tagliaferri, M.D., President and Chief Medical Officer at Bionovo.

"I am very encouraged by the findings of this clinical trial. The novel mechanism of action and phase 2 efficacy and safety results are encouraging and warrant further investigation. Presuming the phase 3 results confirm the findings in the phase 2 trial, there seems no question that, if approved, Menerba's safety and efficacy profile could make it a first line therapy in an indication that clearly needs alternatives," said Wulf Utian, M.D., Ph.D., D.Sc., founder and President Emeritus of the North American Menopause Society and Menerba's phase 3 Principal Clinical Investigator.

Menerba

Menerba is an estrogen receptor (ER) beta selective drug developed as an alternative to postmenopausal hormone products currently on the market, which are both ER beta and ER alpha agonists that have been shown to increase the risk for breast and uterine cancers. It has been shown that the increased risk of breast and uterine cancers is associated with ER alpha activation and that ER beta blocks the growth promoting effects on breast cancer cells. Bionovo recognized the opportunity to commercialize a product that would be equally effective, with an improved safety profile compared to traditional hormone therapy. The clinical trial results have been evaluated by an independent Data and Safety Monitoring Board and the drug candidate has passed through a standard two-phase examination for safety.

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Bionovo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Bionovo Presents Positive Results from Phase 1B Trial of Bezielle for Metastatic Breast Cancer
2. Bionovo to Present at the BMO Capital Markets Ninth Annual Focus on Healthcare Conference
3. Bionovo Announces Arbitration Decision in Lawsuit Filed by Former Officer - All Claims Denied
4. Bionovo, Inc. to Announce First Quarter Fiscal Year 2009 Financial Results on Thursday, May 7, 2009
5. Bionovo to Present at the Cambria Capital Investor Meeting
6. Bionovo to Present at Wall Street Analyst Forums 20th Annual Institutional Investor Conference
7. Bionovo, Inc. to Announce Fourth Quarter and Year-End Financial Results on Thursday, March 12, 2009
8. Jan Ake Gustafsson, M.D., Ph.D., Joins Bionovos Scientific Advisory Board
9. Bionovo Announces Presentation at the National Cancer Institute
10. Bionovo Announces Cost Control Measures Taken
11. Willa A. Hsueh, M.D., Joins Bionovos Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... New York City based oral and maxillofacial surgeon Dr. ... very effective way to treat obstructive sleep apnea. Dr. Jamali is proud to offer this ... procedure that involves one or both jaw bones. This surgery is performed to correct the ...
(Date:4/29/2016)... ... April 29, 2016 , ... Regenerative Medicine Solutions (RMS) scored ... satisfaction survey, earning them second place for Tampa’s Best Places to Work. They were ... “This is a great accomplishment for our team,” says RMS Human Resources Manager Irene ...
(Date:4/29/2016)... ... , ... International Dehydrated Foods, Inc. (IDF™) will attend and sponsor Global Food ... by Hilton Hotel in Oak Brook, Illinois. The two-day event is the largest conference ... , At the seminar, IDF™ will offer samples of its Savory Bone Broth ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... clinic data for 2014. Each year, reproductive endocrinologists are required to report ... the main organization of professionals dedicated to the practice of assisted reproductive technologies ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... providers, recently announced that their founders, Dr. Gemmi and Dr. Middleberg, were asked ... 550 orthodontists around the nation. During the seminar, titled “Advancing the Biomechanics ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... April 27, 2016 Elekta today ... platform will be the focal point of seven scientific ... European Society for Radiotherapy & Oncology, taking place April ... a state-of-the-art radiotherapy system and a high-field MRI scanner ... see the patient,s anatomy in real time. The MR-linac ...
(Date:4/27/2016)... Massachusetts , April 27, 2016 ... that Jeff Poulton , Chief Financial Officer, will present ... Boston, MA on Wednesday, May 04, ... audio webcast will be available on the Presentations and Webcasts ... a replay of the webcast will be available on this ...
(Date:4/27/2016)... At the Sachs CEO forum ... Phase 2 clinical study of its lead drug candidate, ... implantation (CI) surgery. This large, placebo-controlled, double-blind, phase 2 ... and France . STR001 ... time of surgery. "Despite advances in cochlear implant technology, ...
Breaking Medicine Technology: